A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with
non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific
enzyme (Dihydroorotate Dehydrogenase) and has shown pre-clinical efficacy in treatment of
non-infectious uveitis. PP-001 will be administered to participants as a single intravitreal
injection in ascending doses.